A new study from Cornell University has strengthened the case for using a specific group of molecules—known as microRNAs—as reliable markers to detect testicular germ cell tumors, the most common solid cancer found in young men.
These findings, published in Scientific Reports, could pave the way for earlier and less invasive cancer detection methods, potentially even before birth.
Testicular germ cell tumors are the leading type of cancer in U.S. males between ages 15 and 39, and their incidence has risen by nearly 40% over the past 50 years.
Fortunately, they are also among the most treatable cancers, with a five-year survival rate of around 95%. These tumors often originate during embryonic development, long before symptoms appear—highlighting the importance of early detection.
Led by Professor Robert Weiss from Cornell’s College of Veterinary Medicine, the research team focused on a group of molecules called microRNAs (miRNAs). These small RNA molecules don’t code for proteins, but they play an essential role in regulating which genes are turned on or off in cells.
Some miRNAs are known to be highly specific to certain types of cancer, making them ideal candidates for use as biomarkers—substances that can signal the presence of disease in the body.
“There’s a big push in cancer diagnosis to move toward less invasive methods like liquid biopsies,” said Weiss. These approaches use a simple blood sample to check for cancer-related markers, instead of relying on surgery or tissue biopsies. “This is a terrific example of the advancement of that technology,” he added.
To explore how miRNAs might be used to detect testicular cancer, the team used a special mouse model developed in Weiss’s lab. This model allowed them to closely control and observe the growth of testicular germ cell tumors, and even force tumor cells to differentiate—meaning to become more specialized, losing their aggressive, stem-cell-like characteristics.
The researchers discovered that a specific cluster of miRNAs called 290–295 in mice is only expressed by undifferentiated testicular cancer cells—the earliest and most aggressive form of the disease.
These miRNAs disappear when the cancer cells differentiate or when treated with drugs like thioridazine or salinomycin. Importantly, this same cluster has a human equivalent known as miRNA 371–373, which has already been proposed as a marker in previous clinical studies.
In their experiments, these miRNAs were not detected in mice with other types of cancer, like mammary tumors, or in those with benign testicular tumors. This level of specificity is crucial in identifying the right patients for early diagnosis and monitoring treatment response without the risk of false positives from unrelated diseases.
The researchers also identified which genes are targeted by these miRNAs. Many of the genes affected are involved in critical cancer-related processes, such as controlling the cell cycle and triggering apoptosis (programmed cell death). This suggests that the miRNAs might not just be indicators of cancer—they may also play a direct role in its development and progression.
This dual role—as both biomarkers and potential treatment targets—makes these miRNAs especially exciting. “If our expectation is confirmed that these miRNAs do have important functional roles,” Weiss said, “then they provide another step as therapeutic targets that we could go after to block tumor growth or metastasis.”
Review and Analysis
This study is a major step forward in understanding testicular germ cell tumors and how they might be detected early—possibly even before birth. What makes the research especially valuable is the use of a mouse model that accurately mimics the human disease.
While the idea of blood-based cancer detection has been around for some time, this research offers one of the most detailed and specific examples to date for testicular cancer.
The findings are promising for future non-invasive tests, such as blood tests to screen for early-stage cancer or monitor recovery after treatment. Since testicular cancer is so treatable when caught early, the ability to detect it before symptoms appear could save lives and reduce the need for aggressive treatments like chemotherapy or surgery.
The fact that these miRNAs are exclusive to malignant testicular tumors makes them much more reliable than many other cancer markers. They may also help doctors distinguish between harmless growths and dangerous ones, reducing unnecessary interventions.
Additionally, understanding the functional role of these miRNAs could lead to new kinds of treatment, especially if scientists can develop ways to block or modify the activity of these molecules. This could slow down or stop the growth of tumors at a very early stage.
In short, this research not only offers hope for earlier and more accurate detection of testicular cancer but also opens new doors for understanding and potentially treating the disease. It highlights how animal models remain essential tools in studying complex human conditions—especially when exploring areas where direct human research is limited or impossible.
For more information about cancer, please see recent studies about the link between dairy food and certain cancers and these common food chemicals may cause cancer.
For more information about cancer, please see recent studies that plant-based diets may reduce risk of colorectal cancer in men, and Low-fat diet may help stop cancer growth.
The research findings can be found in Scientific Reports.
Copyright © 2025 Knowridge Science Report. All rights reserved.
